Aliskiren

Research use only, not for human use.

The first in a class, potent and highly selective, direct renin inhibitor with IC50 of 0.6 nM.

The first in a class, potent and highly selective, direct renin inhibitor with IC50 of 0.6 nM; no significant inhibition on Cathepsin D, Cathepsin E, Pepsin and HIV-1 peptidase (> 50 uM); orally bioactive.Hypertension Approved.

——

Aliskiren (< 10 mg/kg, Orally, daily) inhibits plasma renin activity and lowers blood pressure in sodium-depleted marmosets.Aliskiren (10 mg/kg, Intragastrically, once) significantly alleviates multiple cachexia?associated symptoms in BALB/c mice bearing C26 mouse colon carcinoma cells, including BW loss, tumor burden, muscle wasting, muscular dysfunction, and shortened survival.

CGP 60536 | CGP60536B | SPP 100

Metabolic Enzyme/Protease

Renin

Renin

Cardiovascular Disease

Hypertension

173334-57-1

551.7583

C30H53N3O6

>98% (HPLC)

10 mM in DMSO

COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(=O)N)C(C)C)ccc1OC

Benzeneoctanamide, .delta.-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-.gamma.-hydroxy-4-methoxy-3-(3-methoxypropoxy)-.alpha.,.zeta.-bis(1-methylethyl)-, (.alpha.S,.gamma.S,.delta.S,.zeta.S)-

(-20℃)

With Ice Pack

≥ 2 years